Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.

Exact Sciences' Q3 earnings report ... the launch of Cologuard Plus, which it seems will be priced higher than the existing test kit. Private insurers and the Centers for Medicaid and Medicare ...

The Cologuard Plus test is now approved for adults ages 45 and older who are average risk for colorectal cancer (CRC).1 MADISON, Wis., September 16, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a ...

Madison-based Exact Sciences Corp. on Tuesday reported third-quarter results worse than analysts expected. The biomedical giant best known for its Cologuard at-home colon cancer screening test ...

Meet Future Greens - a team of University of Sheffield alumni (including a co-founder from Computer Science) aiming to change farming as we know it with their urban vertical farm. New research set to ...

Current price $52.58 52-week high $79.62 ...